Santen and UCL to collaborate on ophthalmic research and education
2 August 2016
Santen Pharmaceutical Co.
The collaboration provides a framework for both parties to work together on ophthalmic research, and translate the research into therapies that can meet unmet medical needs. The framework will also pave the way for both parties to collaborate on capability and talent development in various fields of ophthalmology.
The MoU was signed by Naveed Shams, Senior Corporate Officer, Chief Scientific Officer and Head of Global R&D of Santen, and Dr. Celia Caulcott, Vice-Provost (Enterprise) at UCL.
"Basic and translational research for ophthalmic diseases is an important strategic target of Santen. We are very excited and honoured to partner with UCL, a world leader in ophthalmic research and education, to expand and deepen our ophthalmic R&D capabilities," said Naveed Shams of Santen. "I believe that this partnership will facilitate our exploration activity to achieve our R&D strategic goals through the collaboration in clinical research, translational research and disease-targeted drug discovery. By leveraging this robust partnership, Santen will be continuously seeking innovative therapeutic opportunities and technology platforms that visualize and fulfil future unmet medical needs in the ophthalmology space."
"UCL is delighted to sign this collaboration agreement with Santen, a world leading ophthalmic pharmaceutical company. This agreement underpins our relationship, which will help accelerate the translation of UCL's world-class research into new medical treatments. It exemplifies UCL's Grand Challenges strategy which looks to bring expertise from UCL and beyond together to solve global health problems," said Dr. Celia Caulcott of UCL.